- Home
- ARQT vs WLY Comparison
ARQT vs WLY Comparison
Compare ARQT & WLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- WLY
- Stock Information
- Founded
- ARQT 2016
- WLY 1807
- Country
- ARQT United States
- WLY United States
- Employees
- ARQT N/A
- WLY N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- WLY Books
- Sector
- ARQT Health Care
- WLY Consumer Discretionary
- Exchange
- ARQT Nasdaq
- WLY Nasdaq
- Market Cap
- ARQT 2.1B
- WLY 2.2B
- IPO Year
- ARQT 2020
- WLY N/A
- Fundamental
- Price
- ARQT $16.93
- WLY $41.43
- Analyst Decision
- ARQT Strong Buy
- WLY
- Analyst Count
- ARQT 7
- WLY 0
- Target Price
- ARQT $19.00
- WLY N/A
- AVG Volume (30 Days)
- ARQT 1.5M
- WLY 366.4K
- Earning Date
- ARQT 11-05-2025
- WLY 09-04-2025
- Dividend Yield
- ARQT N/A
- WLY 3.43%
- EPS Growth
- ARQT N/A
- WLY N/A
- EPS
- ARQT N/A
- WLY 1.78
- Revenue
- ARQT $263,464,999.00
- WLY $1,670,600,000.00
- Revenue This Year
- ARQT $72.46
- WLY $1.45
- Revenue Next Year
- ARQT $32.00
- WLY $2.70
- P/E Ratio
- ARQT N/A
- WLY $23.26
- Revenue Growth
- ARQT 99.50
- WLY N/A
- 52 Week Low
- ARQT $8.03
- WLY $36.10
- 52 Week High
- ARQT $18.15
- WLY $53.96
- Technical
- Relative Strength Index (RSI)
- ARQT 57.20
- WLY 55.68
- Support Level
- ARQT $15.13
- WLY $36.10
- Resistance Level
- ARQT $18.15
- WLY $42.25
- Average True Range (ATR)
- ARQT 0.67
- WLY 1.11
- MACD
- ARQT 0.08
- WLY 0.18
- Stochastic Oscillator
- ARQT 60.00
- WLY 86.67
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About WLY John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.